Perosphere Technologies Presents New Clinical Findings for ClotChek™ Coagulometer

On September 8, 2026, Perosphere Technologies Inc., a pioneering medical technology firm, unveiled new clinical evidence supporting its innovative coagulation diagnostic tool, the ClotChek™. This groundbreaking tool is designed to provide next-generation coagulation diagnostics, specifically tailored for patients undergoing treatment with Factor Xa inhibitors like apixaban and rivaroxaban. The recent study showcasing ClotChek™ was published in the peer-reviewed journal, Thrombosis and Haemostasis, further validating its clinical utility.

The study primarily assessed the ClotChek Clotting Time (CKCT) in patients taking these anti-coagulant medications, affirming that the device is highly sensitive to Direct Oral Anticoagulants (DOACs). The research found a strong correlation between CKCT results and DOAC-related anti-FXa drug levels when patients were placed into categories defined by clinically meaningful Medical Decision Limits (MDL). Notably, the device demonstrated its capability to detect significant anticoagulation at essential thresholds of >75 ng/mL and >30 ng/mL MDL.

Dr. Sasha Bakhru, the CEO of Perosphere and a co-author of the study, commented, "These findings underline ClotChek's potential in satisfying a critical clinical need for rapid, bedside evaluations of DOAC anticoagulant effects. This is especially vital in scenarios where timing is crucial, such as during major bleeding events, acute ischemic strokes, trauma situations, or emergency surgeries."

One of the significant advantages of the ClotChek™ system is its ability to deliver pharmacodynamic measurements of a patient's coagulation status directly from whole blood samples, without requiring any reagents. This feature is particularly beneficial when assessing patients at lower drug concentrations, which can be critical when making urgent treatment decisions. As Dr. Jack Ansell, a co-author and former Chair of the Department of Medicine at Lenox Hill Hospital, stated, "Without rapid and objective assessments of anticoagulation status, clinicians may be left with narrow options, potentially delaying or forgoing urgent interventions."

The research acknowledged the contributions of Drs. Bakhru, Connors, Ansell, and Giugliano from the TIMI Study Group, along with other principal investigators associated with this significant work, which enhances the landscape of point-of-care coagulation testing.

Perosphere Technologies aims to improve clinical decision-making with its point-of-care diagnostics, especially for patients on anticoagulant therapy or those at risk of bleeding. The ClotChek™ device swiftly measures whole blood clotting time, achieving results within 3 to 8 minutes, facilitating timely clinical responses.

It is noteworthy that the ClotChek™ has received CE marking in the European Union, although it has not yet been cleared by the FDA for use in the United States. Medical professionals can learn more about this pioneering technology and its applications on the Perosphere website.

In conclusion, as the demand for efficient and effective coagulation diagnostics rises, Perosphere Technologies continues to stand at the forefront, developing solutions that not only enhance patient care but also support medical professionals in making informed decisions swiftly and accurately.